Intrapancreatic Accessory Spleen: Diagnosis with RES-Specific Contrast-Enhanced MRI
2nd Department of Radiology, Pisa University Hospital, Pisa 56124, Italy. American Journal of Roentgenology
(Impact Factor: 2.73).
06/2005; 184(5):1712-3. DOI: 10.2214/ajr.184.5.01841712
Available from: Kamil Hakan Dogan
- "Quah et al. (2010) recently reported that the sensitivity of CT scan before laparoscopic splenectomy in detecting AS was 60%, whereas the sensitivity of laparoscopy in detecting AS was 93%. It was also reported that Tc- 99m heat denatured red blood cell SPECT technique and reticuloendothelial system-specific contrastenhanced MRI may be used for detecting AS (Phom et al., 2001; Boraschi et al., 2005). "
[Show abstract] [Hide abstract]
ABSTRACT: Accessory spleens (AS) may be formed during embryonic development when some of the cells from the developing spleen are deposited along the path from the midline, where the spleen forms, over to its final location on the left side of the abdomen. An accessory spleen is usually near the spleen's hilum, but it may be embedded partly or wholly in the tail of the pancreas. The aim of this study was to investigate the incidence and distribution of AS during routine forensic autopsies. AS were investigated in 720 consecutive autopsy cases. Fifty-four AS were found in 48 (6.7%) cases. AS were found in hilum of the main spleen in 28 cases, the great omentum in 13 cases, the pancreas in 5 cases, and the pelvis in 2 cases. There were two AS in two cases and three AS in another two cases. Awareness of the possible presence of AS is important because when splenectomy is performed for some conditions such as immune thrombocytopenic purpura, failure to remove the AS may result in the failure of the condition to resolve. Additionally, during medical imaging, AS may be confused for enlarged lymph nodes or neoplastic growths. In conclusion, autopsy series are useful for determining the incidences and the other features of AS in different populations, in addition to those studies using CT scans and those studies obtained during laparoscopic or open surgeries.
Available from: Junghwan Oh
- "Early studies demonstrated that SPIO nanoparticles can improve the detection of liver metastases in patients . After SPIO nanoparticles have been administrated intravenously, tissue-based macrophages (Kupffer cells) in the body take up SPIO nanoparticles through the reticuloendothelial system (RES) including bone marrow , hepatic lesions , lymph node metastases in cancer  , and spleen . Compared to conventional ultrasound contrast agents, magnetically activated SPIO nanoparticles have several advantages, including small size, strong magnetic susceptibility, and bio-safety. "
[Show abstract] [Hide abstract]
ABSTRACT: The purpose of this study was to demonstrate the magneto-motive ultrasonic detection of superparamagnetic iron oxide (SPIO) nanoparticles as a marker of macrophage recruitment in tissue. The capability of ultrasound to detect SPIO nanoparticles (core diameter ∼20 nm) taken up by murine liver macrophages was investigated. Eight mice were sacrificed two days after the intravenous administration of four SPIO doses (1.5, 1.0, 0.5, and 0.1 mmol Fe/kg body weight). In the iron-laden livers, ultrasound Doppler measurements showed a frequency shift in response to an applied time-varying magnetic field. M-mode scan and colour power Doppler images of the iron-laden livers also demonstrated nanoparticle movement under focused magnetic field excitation. In the livers of two saline injected control mice, no movement was observed using any ultrasound imaging modes. The results of our experiments indicate that ultrasound imaging of magneto-motive excitation is a candidate imaging modality to identify tissue-based macrophages containing SPIO nanoparticles.
Available from: utexas.edu
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.